When in the process did you identify those specific toxicities?

So, you know, initially when we were still getting used to the regimen, we were learning more about what to expect.

But after we were treating more patients, you know, we realized that, you know, the rash onset with infortimab-vidotin was clearly happening, you know, within the first cycle of treatment is when we would typically see it.

And so usually, actually, the median onset from our retrospective data at our institution showed that people were developing rash within the first two weeks of treatment, actually.

Yeah.

And then from neuropathy, we saw that patients were tending to develop that over time.

It was more of a cumulative toxicity.

Are you using any special tools for your analysis to better understand these drivers?